Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial

South China Morning Post - Nov 3, 2026

An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid last week. Researchers said the drug, iza-bren, showed a significant advantage over platinum-based chemotherapy in a phase 3 randomised, double-blind clinical trial conducted at 73 hospitals in China and involving 432 patients with advanced lung cancer. The median progression-free survival (PFS) – the length of...

Read full article

MORE NEWS

The Life Voyager

The Life Voyager puts travel news into perspective, bringing you unique and secluded side to popular travel destinations you never know exist.

NEWSLETTER